Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy of intravitreal aflibercept therapy using a treat-and-extend regimen on treatment-naïve pachychoroid neovasculopathy (PNV) and Type 1 neovascular age-related macular degeneration (AMD).

Methods

We retrospectively studied 42 eyes with PNV and 60 eyes with Type 1 neovascular AMD. We assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and total number of injections over 2 years.

Results

The BCVA and CMT improvements during the 2-year treatment period did not differ significantly between PNV and AMD; however, CCT decreased significantly in PNV than in AMD (P<0.05). Management of PNV required significantly fewer injections than AMD during the 2-year period (P<0.05). There were no significant differences in BCVA, CMT and CCT changes between PNV with and without polypoidal lesions (28 vs. 14 eyes) during the 2 year period. Significantly fewer injections were needed for PNV with polypoidal lesions than for PNV without (P<0.01). There were no significant differences in BCVA, CMT and CCT changes, or in the number of injections during the 2-year treatment period, between AMD with and without polypoidal lesions (30 vs. 30 eyes).

Conclusion

Treat-and-extend regimen of intravitreal aflibercept injection may be equally effective in terms of improvement of BCVA and exudative changes both in eyes with PNV and those with Type 1 neovascular AMD requiring fewer injections for the former. Among eyes with PNV, those with polypoidal lesions needed fewer injections than those without polypoidal lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1–9.

    Article  CAS  PubMed  Google Scholar 

  2. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659–72.

    Article  PubMed  Google Scholar 

  3. Coscas G, Yamashiro K, Coscas F, De Benedetto U, Tsujikawa A, Miyake M, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol. 2014;158:309–18.

    Article  PubMed  Google Scholar 

  4. Miyake M, Ooto S, Yamashiro K, Takahashi A, Yoshikawa M, Akagi-Kurashige Y, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5:16204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Article  CAS  PubMed  Google Scholar 

  6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.

    Article  CAS  PubMed  Google Scholar 

  7. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–70.

    Article  PubMed  Google Scholar 

  8. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–12.

    Article  CAS  PubMed  Google Scholar 

  10. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58.

    Article  CAS  PubMed  Google Scholar 

  11. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.

    Article  PubMed  Google Scholar 

  12. Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol. 2015;159:3–8.

    Article  PubMed  Google Scholar 

  13. Gass JD. Stereoscopic atlas of macular diseases. 4th ed. St. Louis: C.V. Mosby; 1997. p. 26–30.

    Google Scholar 

  14. Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.

    Article  PubMed  Google Scholar 

  15. Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, et al. Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina. 2016;36:2282–9.

    Article  CAS  PubMed  Google Scholar 

  16. Yanai H. Statcel—the useful add-in software forms on excel. 4th ed. Tokyo: OMS; 2015.

    Google Scholar 

  17. Hata M, Yamashiro K, Ooto S, Oishi A, Tamura H, Miyata M, et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:292–8.

    Article  CAS  PubMed  Google Scholar 

  18. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456–62.

    Article  CAS  PubMed  Google Scholar 

  19. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119:1621–7.

    Article  PubMed  Google Scholar 

  20. Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology. 2016;123:617–24.

    Article  PubMed  Google Scholar 

  21. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054–8.

    CAS  PubMed  Google Scholar 

  22. Kim YK, Ryoo NK, Woo SJ, Park KH. Choroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;160:72–84.

    Article  PubMed  Google Scholar 

  23. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:594–603.

    Article  CAS  PubMed  Google Scholar 

  24. Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Gunma University, School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Hidetaka Matsumoto, Takashi Hiroe, Masahiro Morimoto, Kensuke Mimura, Arisa Ito & Hideo Akiyama

Authors
  1. Hidetaka Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Hiroe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiro Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kensuke Mimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arisa Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideo Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidetaka Matsumoto.

Ethics declarations

Conflicts of interest

H. Matsumoto, None; T. Hiroe, None; M. Morimoto, None; K. Mimura, None; A. Ito, None; H. Akiyama, None.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsumoto, H., Hiroe, T., Morimoto, M. et al. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62, 144–150 (2018). https://doi.org/10.1007/s10384-018-0562-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-018-0562-0

Keywords

Search

Navigation